A phase II, multicentre, double-blind, randomised, placebo-controlled study on efficacy and tolerability of Rifaximin vaginal tablets in the treatment of bacterial vaginosis.

Trial Profile

A phase II, multicentre, double-blind, randomised, placebo-controlled study on efficacy and tolerability of Rifaximin vaginal tablets in the treatment of bacterial vaginosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Bacterial vaginosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms VARIANT 1
  • Sponsors Alfa Wassermann SpA
  • Most Recent Events

    • 21 Apr 2012 Additional location (Germany) added as reported by European Clinical Trials Database record.
    • 15 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top